Miromatrix Inc. is among a select group of companies receiving the KidneyX Redesign Dialysis Phase I award. Jeff Ross, Ph.D. and Miromatrix CEO, will accept the $75,000 prize and present on their approach to end dialysis through bioengineering transplantable kidneys during the KidneyX Summit in Washington, D.C. April 29-30.
KidneyX, also called the Kidney Innovation Accelerator, is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN). Established in April 2018, KidneyX seeks to improve the lives of the 850 million people worldwide currently affected by kidney diseases by accelerating the development of drugs, devices, biologics and other therapies across the spectrum of kidney care. Beyond awarding potentially breakthrough ideas, KidneyX is aligning NIH, FDA and CMS to provide a clearer, more predictable path to market for innovators.
"We’re thrilled to be chosen as a KidneyX prize recipient! It's such an honor to be recognized for the groundbreaking work we're doing to develop fully functional transplantable kidneys,” says Dr. Ross. “Today, more than 700,000 Americans are living with kidney failure that require dialysis or transplantation, and unfortunately, less than half of the patients who start dialysis will survive 5 years, compared to over 90% of patient survival for those fortunate to receive a kidney transplant. Our mission is to dramatically reduce the number of patients on dialysis, as well as save millions of lives by eliminating the kidney transplant waiting list.”
KidneyX aims to use prize competitions to accelerate the development of innovative solutions that can prevent, diagnose, and/or treat kidney diseases, with the ultimate goal of improving the quality of life for the more than 40 million Americans living with those diseases. For more information about KidneyX, visit kidneyx.org/.